Parallel Advisors LLC lifted its stake in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 247.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,685 shares of the biotechnology company’s stock after purchasing an additional 1,200 shares during the period. Parallel Advisors LLC’s holdings in Heron Therapeutics were worth $41,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Heron Therapeutics by 36.7% during the 3rd quarter. Vanguard Group Inc. now owns 6,193,249 shares of the biotechnology company’s stock worth $196,016,000 after purchasing an additional 1,661,318 shares during the last quarter. BlackRock Inc. grew its stake in Heron Therapeutics by 2.8% in the 4th quarter. BlackRock Inc. now owns 4,913,006 shares of the biotechnology company’s stock valued at $127,443,000 after buying an additional 132,207 shares in the last quarter. D. E. Shaw & Co. Inc. grew its stake in Heron Therapeutics by 81.4% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,054,008 shares of the biotechnology company’s stock valued at $27,341,000 after buying an additional 473,127 shares in the last quarter. Geode Capital Management LLC grew its stake in Heron Therapeutics by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 751,250 shares of the biotechnology company’s stock valued at $19,487,000 after buying an additional 26,429 shares in the last quarter. Finally, Norges Bank purchased a new position in Heron Therapeutics in the 4th quarter valued at approximately $13,679,000.
A number of research analysts recently weighed in on the stock. Cowen reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, May 9th. Northland Securities reiterated a “buy” rating and issued a $55.00 price objective on shares of Heron Therapeutics in a research note on Thursday, May 9th. Zacks Investment Research lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 9th. ValuEngine lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $38.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, May 1st. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $51.20.
Shares of NASDAQ:HRTX opened at $18.12 on Thursday. The company has a quick ratio of 4.06, a current ratio of 4.40 and a debt-to-equity ratio of 0.04. Heron Therapeutics Inc has a one year low of $16.20 and a one year high of $42.90. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -7.43 and a beta of 1.45.
Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.30). Heron Therapeutics had a negative net margin of 194.43% and a negative return on equity of 49.22%. The firm had revenue of $31.60 million during the quarter, compared to the consensus estimate of $28.04 million. During the same period in the previous year, the business earned ($1.09) earnings per share. The firm’s revenue for the quarter was up 172.4% on a year-over-year basis. On average, equities analysts expect that Heron Therapeutics Inc will post -1.95 earnings per share for the current fiscal year.
Heron Therapeutics Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
See Also: Futures Contract
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.